Source link : https://newshealth.biz/health-news/sacituzumab-govitecan-gains-first-line-tnbc-indications/
Sacituzumab govitecan is the first ADC approved for upfront metastatic triple-negative breast cancer regardless of PD-L1 inhibitor eligibility. Medscape Medical News Source link : https://www.medscape.com/viewarticle/sacituzumab-govitecan-gains-first-line-tnbc-indications-2026a1000lod?src=rss Author : Publish date : 2026-06-25 16:29:00 Copyright for syndicated content belongs to the linked Source.
The post Sacituzumab Govitecan Gains First-Line TNBC Indications first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-25 16:29:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8